<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216827</url>
  </required_header>
  <id_info>
    <org_study_id>MBL 0405 INT</org_study_id>
    <nct_id>NCT00216827</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis</brief_title>
  <official_title>Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of
      calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more
      effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50
      mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis.

      The primary outcome is the proportion of patients with absence of disease or very mild
      disease after 8 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall disease severity according to investigator's assessment at week 8</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total sign score at week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for scaliness, redness and thickness at week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of scalp psoriasis at week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease severity according to investigator's assessment at week 2 and 4</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease severity according to patients at week 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data</measure>
  </secondary_outcome>
  <enrollment>1485</enrollment>
  <condition>Psoriasis of Scalp</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus betamethasone dipropionate (LEO80185 gel)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Scalp psoriasis amenable to topical treatment

          -  Psoriasis vulgaris on trunk and/or limbs

          -  Extent of scalp psoriasis involving more than 10% of the total scalp area

          -  Disease severity on the scalp graded as mild or worse by the investigator

          -  Consenting out-patients of 18 years or above

        Main Exclusion Criteria:

          -  PUVA or Grenz ray therapy within 4 weeks prior to randomisation

          -  UVB therapy within 2 weeks prior to randomisation

          -  Systematic treatment with biological therapies, with a possible effect on scalp
             psoriasis within 6 months prior to randomisation

          -  Systemic treatment with all other therapies than biologicals, with a possible effect
             on scalp psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids,
             immunosuppressants) within 4 weeks prior to randomisation

          -  Any topical treatment of the scalp (except for medicated shampoos and emollients)
             within 2 weeks prior to randomisation

          -  Topical treatment of the face, trunk and/or limbs with very potent WHO group IV
             corticosteroids within 2 weeks prior to randomisation

          -  Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor Jemec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roskilde Hospital, Division of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FRCPC, Centre de Recherche Dermatologique du Quebec Metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital, Division of Dermatology</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet, Service de Dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudlegekontoret</name>
      <address>
        <city>Sandvika</city>
        <zip>1338</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra, Servico de dermatologia</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena, Servicio de Dermatología</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset, Hudkliniken</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary, Dermatology Department</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

